Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$14.32
+0.1%
$12.39
$8.02
$15.78
$7.10B1.675.10 million shs5.61 million shs
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$1.69
-2.9%
$2.30
$1.64
$12.51
$564.35M0.869.01 million shs17.46 million shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$32.58
-0.9%
$33.26
$27.66
$121.06
$4.20B1.21.47 million shs5.90 million shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$62.73
+2.1%
$62.45
$40.46
$69.89
$3.99B2.3551,282 shs857,993 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.00%+6.32%+6.91%+37.71%-20.34%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-2.87%-14.65%-3.43%-52.53%-79.16%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-0.91%-0.88%+3.82%-53.10%-56.59%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
+2.10%+1.19%+5.27%+14.47%+57.34%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
1.789 of 5 stars
1.34.00.00.31.31.70.6
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
4.6671 of 5 stars
4.31.00.04.21.84.21.3
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
2.9143 of 5 stars
4.61.00.00.03.21.70.0
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
3.8003 of 5 stars
3.52.00.04.31.50.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.50
Moderate Buy$15.175.95% Upside
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
2.50
Moderate Buy$12.22623.21% Upside
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.10
Buy$136.50318.97% Upside
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
3.00
Buy$77.3123.24% Upside

Current Analyst Ratings Breakdown

Latest IOVA, ELAN, PCVX, and RYTM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
6/26/2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$84.00
5/29/2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$78.00 ➝ $94.00
5/19/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $16.00
5/16/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$17.00 ➝ $2.00
5/12/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $8.00
5/12/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$30.00 ➝ $10.00
5/12/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.00
5/12/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
5/9/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/9/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Perform
(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.44B1.60$2.26 per share6.34$12.33 per share1.16
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$164.07M3.44N/AN/A$2.33 per share0.73
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/A$26.52 per shareN/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$130.13M30.67N/AN/A$0.35 per share179.23
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$338M$0.7419.3416.082.808.43%7.54%3.57%8/6/2025 (Estimated)
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$372.18M-$1.24N/AN/AN/A-176.49%-49.71%-39.18%8/6/2025 (Estimated)
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$463.93M-$3.99N/AN/AN/AN/A-17.12%-16.26%8/5/2025 (Estimated)
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$260.60M-$2.81N/AN/AN/A-123.26%-739.62%-44.27%8/5/2025 (Estimated)

Latest IOVA, ELAN, PCVX, and RYTM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$1.02-$1.04-$0.02-$1.04N/AN/A
5/8/2025Q1 2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$0.25-$0.36-$0.11-$0.36$83.40 million$49.32 million
5/7/2025Q1 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.31$0.37+$0.06$0.14$1.17 billion$1.19 billion
5/7/2025Q1 2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$0.69-$0.81-$0.12-$0.81$40.43 million$37.72 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
N/AN/AN/AN/AN/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/AN/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.68
2.71
1.46
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
N/A
4.18
3.64
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/A
17.70
17.70
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
3.30
3.13

Institutional Ownership

CompanyInstitutional Ownership
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
77.03%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
96.78%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.89%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
10.30%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.10%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
6.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,000496.65 million492.23 millionOptionable
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
500333.93 million299.54 millionOptionable
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
160129.00 million125.01 millionOptionable
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
14063.62 million59.74 millionOptionable

Recent News About These Companies

Rhythm & Food community BBQ
Rhythm Pharmaceuticals, Inc. (RYTM) - Yahoo Finance
Rhythm Pharmaceuticals: Growth Is Expected To Go Parabolic
Rhythm and Blues Show

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$14.32 +0.02 (+0.10%)
Closing price 06/27/2025 03:59 PM Eastern
Extended Trading
$14.28 -0.04 (-0.24%)
As of 06/27/2025 06:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Iovance Biotherapeutics stock logo

Iovance Biotherapeutics NASDAQ:IOVA

$1.69 -0.05 (-2.87%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$1.72 +0.03 (+1.48%)
As of 06/27/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Vaxcyte stock logo

Vaxcyte NASDAQ:PCVX

$32.58 -0.30 (-0.91%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$33.20 +0.63 (+1.92%)
As of 06/27/2025 05:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Rhythm Pharmaceuticals stock logo

Rhythm Pharmaceuticals NASDAQ:RYTM

$62.73 +1.29 (+2.10%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$62.81 +0.08 (+0.13%)
As of 06/27/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.